Mortallity (0 to 30 days · adults undergoing cardiac surgery without cardiopulmonary bypass
It is very uncertain whether epidural analgesia changes mortallity (0 to 30 days compared with peripheral nerve blocks (very low certainty).
1 finding from 1 review
Days until 420 joules per kilogram · exclusively formula‐fed preterm or low birth weight infants
1 finding from 1 review
Intervention not reported
Complications of surgery (haemorrhage and days with pain) · children with PFAPA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Severity of episodes (number of days with fever and the associated symptoms (per episode)) · children with PFAPA
The intervention showed no clear difference in severity of episodes (number of days with fever and the associated… (moderate certainty).
1 finding from 1 review
Rate of weight gain (g/kg/day) · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
1 finding from 1 review
Rate of weight gain (g/kg/day) · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
1 finding from 1 review
Rate of weight gain (g/kg/day) · children aged 6 months‐5 years with SAM (1 study included HIV‐uninfected children; 1 study included HIV‐infected children), all of whom…
1 finding from 1 review
Duration of neutropaenia (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Length of hospitalisation (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Duration of antimicrobial treatment (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Fever clearance time · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Duration of neutropaenia (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Length of hospitalisation (days) · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Fever clearance time · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Percent of days abstinent · co‐occurring depression and substance use disorders
2 findings from 1 review
Percent of days abstinent · co‐occurring depression and substance use disorders
1 finding from 1 review
Weight loss rate up to day 10 after treatment · patients of all ages with oedema due to nephrotic syndrome
1 finding from 1 review
Intervention not reported
Hospital stay in days · patients older than 50 years with asymptomatic PAA
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
All‐cause mortality Up to 28 days following admission · individuals with influenza
It is very uncertain whether corticosteroid therapy changes number of deaths at 30 days following admission (30‐day mortality)a compared with no corticosteroid therapy (very low certainty).
1 finding from 1 review
Return to work · patients with coronary heart disease
1 finding from 1 review